Pentamidine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
Neil.m.young (talk | contribs) (Text replacement - "4 mg" to "4mg") |
||
| Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*PCP treatment, mod-severe: | *PCP treatment, mod-severe: 4mg/kg IV/IM qd x21 days | ||
**Not 1st-line agent; may consider decreasing dose to 3mg/kg IV/IM qd if toxicities occur | **Not 1st-line agent; may consider decreasing dose to 3mg/kg IV/IM qd if toxicities occur | ||
| Line 13: | Line 13: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*PCP treatment [for >4 mo]: | *PCP treatment [for >4 mo]: 4mg/kg IV/IM qd x21 days | ||
**Not 1st-line agent | **Not 1st-line agent | ||
**Consider decreasing dose to 3mg/kg IV/IM qd if toxicities occur | **Consider decreasing dose to 3mg/kg IV/IM qd if toxicities occur | ||
Revision as of 13:14, 21 July 2016
Administration
- Type: Antifungal Agent; Antiprotozoal
- Routes of Administration: IM, IV
- Common Trade Names: Pentam
Adult Dosing
- PCP treatment, mod-severe: 4mg/kg IV/IM qd x21 days
- Not 1st-line agent; may consider decreasing dose to 3mg/kg IV/IM qd if toxicities occur
- PCP prophylaxis: 300mg NEB q4wk
- Not 1st-line agent; use injectable product via nebulizer; reconstitute 1 vial with 6 mL sterile water; do not mix with other nebulized meds
- Off label use
Pediatric Dosing
- PCP treatment [for >4 mo]: 4mg/kg IV/IM qd x21 days
- Not 1st-line agent
- Consider decreasing dose to 3mg/kg IV/IM qd if toxicities occur
- Switch to PO regimen to complete course if improvement after 7-10 days
- PCP prophylaxis [>5 yo]: 300mg NEB q4wk
- Not 1st-line agent
- Use injectable product via nebulizer; reconstitute 1 vial with 6 mL sterile water
- Do not mix with other nebulized meds
- Off label use
Special Populations
- Pregnancy Risk Factor C
Renal Dosing
- CrCl <10: give q24-36h
- HD: give 750mg supplement
- PD: no supplement
Hepatic Dosing
- Caution advised with hepatic impairment
Contraindications
- Allergy to class/drug
- congenital long QT syndrome
- electrolyte abnormalities, uncorrected
- caution if QT prolongation
Adverse Reactions
Serious
- extravasation/tissue damage
- hypoglycemia
- hyperglycemia
- diabetes mellitus
- pancreatitis
- nephrotoxicity
Common
- renal dysfunction
- BUN, Cr elevated
- injection site necrosis
- leukopenia
- transaminitis
Pharmacology
- Half-life: 2-4 weeks
- Metabolism: Liver
- Excretion: Urine
Mechanism of Action
protozocidal - interferes with nuclear metabolism
Comments
See Also
References
<Epocrates, UpToDate>